Kun-Peng Zhu (Kunpeng Zhu)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Artificial Intelligence

End Stage Renal Disease

Prognostic Factors

Ejection Fraction

Top Venues

Clinical and translational medicine

Cell death discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Yongjie Wang, Xiaolong Ma, Enjie Xu, Zhen Huang, Chen Yang, Kun-Peng Zhu, Yang Dong, Chun-Lin Zhang
Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index. Clinical and translational medicine 14 (2) (2024)
Yongjie Wang, Xiaolong Ma, Enjie Xu, Zhen Huang, Chen Yang, Kun-Peng Zhu, Yang Dong, Chun-Lin Zhang
Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index. Clinical and translational medicine 14 (2) (2024)
Yongjie Wang, Xiaolong Ma, Enjie Xu, Zhen Huang, Chen Yang, Kun-Peng Zhu, Yang Dong, Chun-Lin Zhang
Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index. Clinical and translational medicine 14 (2) (2024)
Yongjie Wang, Xiaolong Ma, Enjie Xu, Zhen Huang, Chen Yang, Kun-Peng Zhu, Yang Dong, Chun-Lin Zhang
Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index. Clinical and translational medicine 14 (2) (2024)
Xiao-Long Ma, Tai-Cheng Zhan, Jian-Ping Hu, Chun-Lin Zhang, Kun-Peng Zhu
Doxorubicin-induced novel circRNA_0004674 facilitates osteosarcoma progression and chemoresistance by upregulating MCL1 through miR-142-5p. Cell death discovery 7 (1) (2021)